Immune fitness and response to taclistamab in R/R multiple myeloma; BCR::ABL1 M244V mutation causes resistance to asciminib; HSCT and myocardial fibrosis in young patients with SCD

In this week's episode we’ll discuss how immune fitness impacts response to teclistamab in relapsed/refractory multiple myeloma; learn more about a new mechanism of resistance to asciminib conferred by the BCR::ABL1 M244V mutation, and discuss the impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease.

Featured Articles:

• Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1
• BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib
• Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease